C6 Lyme ELISA™

Increase confidence in your diagnosis by making the C6 Lyme ELISA test your **first step** in Lyme disease testing.

The C6 Lyme ELISA test has years of proven performance and dozens of peer-reviewed clinical studies substantiating its use. For many years, leading Lyme disease scientists have relied upon the C6 Lyme ELISA test in their clinical investigations. These studies show that the C6 Lyme ELISA test delivers results that are virtually equivalent to a two-tier protocol of other serological assays,[1] and it is effective in detecting all major infectious *Borrelia* species.[2]

Oxford Immunotec

Clinical Challenge

Need for more reliable Lyme disease testing

- Low specificity of most ELISA tests leads to high false positive rates.[1]
- Western Blot is often used as confirmatory test to reduce false positives as part of a two-tier protocol – adding time and cost to the diagnostic process.[3]

Solution

Use the C6 Lyme ELISA test as the **first step**

- By eliminating the majority of false positive results, the C6 Lyme ELISA test reduces the time and money spent on unnecessary Western Blot tests.

Benefits of the C6 Lyme ELISA test

The C6 Lyme ELISA test delivers the following critical advantages:

1

Virtual equivalence to two-tier protocol in a single screening assay:[1]

- Superior sensitivity
- Similar specificity

2

Proven detection of major infectious European species (*B. afzelii, B. garinii, B. burgdorferi*)[4]

3

Low cross-reactivity with other disease conditions[1]

Efficiency, Reliability and Accuracy

What makes the C6 Lyme ELISA test so effective?

Only the C6 Lyme ELISA test utilizes the C6 peptide, a 26-amino acid sequence within the *Borrelia* membrane protein VlsE, which is specific to the *Borrelia* spirochete

- Generates an immune response in nearly all human cases after infection.
- Is specific to *Borrelia* strains causing Lyme disease.[5]
- Is not found in other infectious organisms, virtually eliminating cross-reactivity.[5]

C6 Lyme ELISA: 1 Antigen



C6 molecules bind only to corresponding antibodies to C6 in the sample.
High specificity

Whole Cell Sonicate ELISA: Multiple Antigens

Mix of antigens bind to a mix of antibodies in the sample; some may be specific but many are not.
Lower specificity

C6 Lyme ELISA test compared to the two-tier method

In many areas, the standard for Lyme disease testing calls for the use of the antiquated two-tier testing method, which has inherent limitations.[1] It calls for an ELISA screen followed by a confirmatory Western Blot for all positive and indeterminate results. However, studies show that a single C6 Lyme ELISA test is virtually equivalent to the two-tier protocol.[1]

Superior sensitivity[1]



Similar specificity[1]



With higher sensitivity to detect early Lyme infection and high specificity to reduce unnecessary false positive results, the C6 Lyme ELISA test is the clear choice to begin the lab testing process.

Reliable diagnosis of Lyme infection is challenging

Get results you can **trust** with the C6 Lyme ELISA test

Your **first step** in Lyme testing

Available for Manual use or for use on Automated Equipment:
Manual Kit: DK-E601-096
Automated Kit: DK-E601-096A

For more information

ITK DIAGNOSTICS BV

Joh. Enschedeweg 13
1422 DR Uithoorn
Postbus 73
1420 AB Uithoorn

Tel.: 0297 - 56 88 93
Fax.: 0297 - 56 34 58
Internet: www.itk.nl
E-mail: info@itk.nl

REFERENCES

1. Wormser GP, Schriefer M, Aguero-Rosenfeld ME, Levin A, Steere AC, Nadelman RB, Nowakowski J, Marques A, Johnson BJ, Dumler JS. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis. 2013 Jan;75(1):9-15. doi: 10.1016/j.diagmicrobio.2012.09.003. PubMed PMID: 23062467; PubMed Central PMCID: PMC4052829.

2. Branda JA, Strle F, Strle K, Sikand N, Ferraro MJ, Steere AC. Performance of United States serologic assays in the diagnosis of Lyme borreliosis acquired in Europe. Clin Infect Dis. 2013 Aug;57(3):333-40. doi: 10.1093/cid/cit235. PubMed PMID: 23592827.

3. Notice to Readers Recommendations for Test Performance and Interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. https://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm. Accessed January 11, 2017.

4. Liang FT, Aberer E, Cinco M, Gern L, Hu CM, Lobet YN, Ruscio M, Voet PE Jr, Weynants VE, Philipp MT. Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi SL. J Infect Dis. 2000 Nov;182(5):1455-62. PubMed PMID: 11023468.

5. Liang FT, Steere AC, Marques AR, Johnson BJ, Miller JN, Philipp MT. Sensitive and specific serodiagnosis of Lyme disease by enzyme-linked immunosorbent assay with a peptide based on an immunodominant conserved region of Borrelia burgdorferi vlsE. J Clin Microbiol. 1999 Dec;37(12):3990-6. PubMed PMID: 10565920; PubMed Central PMCID: PMC85863.

IMMUNETICS

Oxford Immunotec

C6-UK-BRCH-0099-V2